http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2009102932-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate | 2007-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2009102932-A |
| titleOfInvention | USE OF RKS INHIBITORS IN COMPLICATIONS CAUSED BY DIABETES |
| abstract | 1. The use of 3- (1H-indol-3-yl) -4- [2- (4-methylpiperazin-1-yl) quinazolin-4-yl] pyrrole-2,5-dione, 3- (1H-indol- 3-yl) -4- [2- (piperazin-1-yl) quinazolin-4-yl] pyrrole-2,5-dione, 3- [3- (4,7-diazaspiro [2.5] oct-7-yl ) isoquinolin-1-yl] -4- (7-methyl-1H-indol-3-yl) pyrrole-2,5-dione or their pharmaceutically acceptable salts for the manufacture of a medicament for treating, preventing or delaying the development of complications, caused by diabetes. ! 2. The use according to claim 1, where the complication is nephropathy, neuropathy or cardiomyopathy. ! 3. The use according to claim 1 or 2, wherein the compound is 3- (1H-indol-3-yl) -4- [2- (4-methylpiperazin-1-yl) quinazolin-4-yl] pyrrol-2 acetate, 5-dione. ! 4. A method of treating or preventing diabetic nephropathy, neuropathy or cardiomyopathy, or slowing their development, which consists in the introduction of an effective amount of 3- (1H-indol-3-yl) -4- [2- (4-methylpiperazin-1-yl) quinazolin-4-yl] pyrrole-2,5-dione, 3- (1H-indol-3-yl) -4- [2- (piperazin-1-yl) quinazolin-4-yl] pyrrole-2,5- dione or their pharmaceutically acceptable salts to a subject in need of such treatment. ! 5. A method of treating or preventing diabetic cardiomyopathy or slowing its development, which is the introduction of an effective amount of 3- [3- (4,7-diazaspiro [2.5] oct-7-yl) isoquinolin-1-yl] -4- (7 -methyl-1H-indol-3-yl) pyrrole-2,5-dione or its pharmaceutically acceptable salts. ! 6. A pharmaceutical composition for treating or preventing diabetes-related complications, and comprising 3- (1H-indol-3-yl) -4- [2- (4-methylpiperazin-1-yl) quinazolin-4-yl] pyrrole -2,5-dione, 3- (1H-indol-3-yl) -4- [2- (piperazin-1-yl) quinazolin-4-yl] pyrrole-2,5-dione, 3- [3- (4,7-diazaspiro [2.5] oct-7-yl) isoquinolin-1-yl] -4- (7-methyl-1H-indol-3-yl) pyrrole-2,5-dione or their pharmaceutical |
| priorityDate | 2006-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 104.